European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Kyle LaHucik

Senior Reporter

Germany-based investor Earlybird Health has closed its second healthcare-focused fund and has already deployed some of it in biopharma and medtech companies, with one exit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Eu­ro­pean in­vestor Early­bird Health clos­es $185M fund to back 12 to 15 com­pa­nies

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

European investor Earlybird Health closes $185M fund to back 12 to 15 companies